Tags

Type your tag names separated by a space and hit enter

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Mov Disord. 2009 Jan 15; 24(1):25-31.MD

Abstract

We aimed to investigate whether treatment with levodopa/carbidopa/entacapone when compared with levodopa/carbidopa improves quality of life in Parkinson's disease (PD) patients with no or minimal, nondisabling motor fluctuations. This is a multicenter, randomized, double-blind study. One hundred eighty-four patients on 3 to 4 equal doses of 100/25 to 200/50 mg levodopa/carbidopa or levodopa/benserazide, 0 to 3 hours of nondisabling OFF time over a 48 hour period and no dyskinesia were randomized to levodopa/carbidopa/entacapone or levodopa/carbidopa treatment for 12 weeks. The primary outcome measure was quality of life as assessed by the PDQ-8. Secondary outcome measures were the UPDRS parts I-IV, and the Wearing Off Card. Treatment with levodopa/carbidopa/entacapone resulted in significantly greater improvements in PDQ-8 scores compared to treatment with levodopa/carbidopa (mean difference 1.4 points, P = 0.021). Statistically significant improvements were seen predominantly in nonmotor domains (depression, personal relationships, communication, stigma, all P < 0.05; dressing P = 0.056). Patients who were randomly assigned to levodopa/carbidopa/entacapone also showed significantly greater improvement in UPDRS part II scores (P = 0.032) with UPDRS part III scores showing borderline significance. Differences in UPDRS parts I and IV and Wearing Off Card scores were not significant. Treatment with levodopa/carbidopa/entacapone results in improved quality of life compared with levodopa/carbidopa in PD patients with mild or minimal, nondisabling motor fluctuations.

Authors+Show Affiliations

Movement Disorder Unit, Department of Neurology, Westmead Hospital, NSW, Australia. vscfung@ozemail.com.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18846551

Citation

Fung, Victor S C., et al. "Quality of Life in Early Parkinson's Disease Treated With Levodopa/carbidopa/entacapone." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 24, no. 1, 2009, pp. 25-31.
Fung VS, Herawati L, Wan Y, et al. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Mov Disord. 2009;24(1):25-31.
Fung, V. S., Herawati, L., & Wan, Y. (2009). Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Movement Disorders : Official Journal of the Movement Disorder Society, 24(1), 25-31. https://doi.org/10.1002/mds.21878
Fung VS, et al. Quality of Life in Early Parkinson's Disease Treated With Levodopa/carbidopa/entacapone. Mov Disord. 2009 Jan 15;24(1):25-31. PubMed PMID: 18846551.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. AU - Fung,Victor S C, AU - Herawati,Lilie, AU - Wan,Ying, AU - ,, AU - ,, PY - 2008/10/11/pubmed PY - 2009/6/6/medline PY - 2008/10/11/entrez SP - 25 EP - 31 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 24 IS - 1 N2 - We aimed to investigate whether treatment with levodopa/carbidopa/entacapone when compared with levodopa/carbidopa improves quality of life in Parkinson's disease (PD) patients with no or minimal, nondisabling motor fluctuations. This is a multicenter, randomized, double-blind study. One hundred eighty-four patients on 3 to 4 equal doses of 100/25 to 200/50 mg levodopa/carbidopa or levodopa/benserazide, 0 to 3 hours of nondisabling OFF time over a 48 hour period and no dyskinesia were randomized to levodopa/carbidopa/entacapone or levodopa/carbidopa treatment for 12 weeks. The primary outcome measure was quality of life as assessed by the PDQ-8. Secondary outcome measures were the UPDRS parts I-IV, and the Wearing Off Card. Treatment with levodopa/carbidopa/entacapone resulted in significantly greater improvements in PDQ-8 scores compared to treatment with levodopa/carbidopa (mean difference 1.4 points, P = 0.021). Statistically significant improvements were seen predominantly in nonmotor domains (depression, personal relationships, communication, stigma, all P < 0.05; dressing P = 0.056). Patients who were randomly assigned to levodopa/carbidopa/entacapone also showed significantly greater improvement in UPDRS part II scores (P = 0.032) with UPDRS part III scores showing borderline significance. Differences in UPDRS parts I and IV and Wearing Off Card scores were not significant. Treatment with levodopa/carbidopa/entacapone results in improved quality of life compared with levodopa/carbidopa in PD patients with mild or minimal, nondisabling motor fluctuations. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/18846551/Quality_of_life_in_early_Parkinson's_disease_treated_with_levodopa/carbidopa/entacapone_ L2 - https://doi.org/10.1002/mds.21878 DB - PRIME DP - Unbound Medicine ER -